Loading…
Lobbying Spend
—
Filings
75
Firms Hired
2
Active Period
2005–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act FY 2023 Omnibus Appropriations Bill
Client expense: — · Firm income: $50,000
Matched citations: HR 7667
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act FY 2023 Omnibus Appropriations Bill
Client expense: — · Firm income: $50,000
Matched citations: S 4333
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act FY 2023 Omnibus Appropriations Bill
Client expense: — · Firm income: $50,000
Matched citations: S 4348
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act
Client expense: — · Firm income: $50,000
Matched citations: HR 7667
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act
Client expense: — · Firm income: $50,000
Matched citations: S 4333
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022 S 4333 The Clear Act
Client expense: — · Firm income: $50,000
Matched citations: S 4348
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022
Client expense: — · Firm income: $50,000
Matched citations: HR 7667
Issues related to FDAs authority to regulate products as drugs and medical devices: S 4348 FDASLA of 2022 HR 7667 Food and Drug Amendments 2022
Client expense: — · Firm income: $50,000
Matched citations: S 4348
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2020 · first_quarter · Firm: Polsinelli PC
H.R. 3772 The Medicare Diagnostic Radiopharmaceutical Equity Act of 2019 CY 2020 Medicare Physician Fee Schedule Proposed Rule Legislation related to Cardiac PET Imaging
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2019 · fourth_quarter · Firm: Polsinelli PC
H.R. 3772 The Medicare Diagnostic Radiopharmaceutical Equity Act of 2019 CY 2020 Medicare Physician Fee Schedule Proposed Rule Legislation related to Cardiac PET Imaging
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2019 · third_quarter · Firm: Polsinelli PC
H.R. 3772 The Medicare Diagnostic Radiopharmaceutical Equity Act of 2019 CY 2020 Medicare Physician Fee Schedule Proposed Rule Legislation related to Cardiac PFT Imaging
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3772
To amend title XVIII of the Social Security Act to revise the NTAP period under the Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient prospective payment system.
2018 · first_quarter · Firm: Polsinelli PC
CY17 CMS HOPPS rule HR 4683 To amend title XVIII of the Social Security Act to revise the NTAP period under the Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient prospective payment system. FY18 Appropriations; Consolidated Appropriations Act 2018
Client expense: — · Firm income: $20,000
Matched citations: HR 4683
To amend title XVIII of the Social Security Act to revise the NTAP period under the Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient prospective payment system.
2017 · fourth_quarter · Firm: Polsinelli PC
CY17 CMS HOPPS rule HR 4683 To amend title XVIII of the Social Security Act to revise the NTAP period under the Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient prospective payment system.
Client expense: — · Firm income: $20,000
Matched citations: HR 4683
Source: Senate LDA